Generics - Pharmaceutical, Cipla

Filter

Current filters:

PharmaceuticalCipla

Popular Filters

India's Cipla ups bid for Cipla Medpro now seeking 100% control for around $512 million

01-03-2013

Indian drugmaker Cipla (BSE: 500087) has made an offer to the shareholders of Cipla Medpro South Africa…

CiplaCipla MedproGenericsMarkets & MarketingPharmaceutical

India's Cipla cuts prices of three cancer drugs

12-11-2012

Following what Indian drugmaker Cipla (BSE: 500087) said was an "overwhelming response" on the price…

Asia-PacificcapecitabineCipladocetaxelerlotinibGenericsOncologyPatentsPfizerPharmaceuticalPricingSunitinib MalateSutent

Another negative Indian patent ruling, this time for Pfizer's Sutent

08-10-2012

In yet another setback for research-based pharmaceutical companies, last week the Indian patent office…

Asia-PacificCiplaGenericsLegalNatco PharmaOncologyPatentsPfizerPharmaceuticalSutent

AstraZeneca drops early-stage obesity drug; Roche loses out on Indian Tarceva dispute

10-09-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) has told its development partner Palatin Technologies…

Asia-PacificAstraZenecaCiplaErlocipGenericsMetabolicsOncologyPalatin TechnologiesPatentsPharmaceuticalResearchRocheTarceva

DNDi and Cipla to develop 4-in-1 pediatric antiretroviral drug combination

24-07-2012

Coinciding with the XIX International AIDS Conference in Washington DC, the Drugs for Neglected Diseases…

Anti-viralsCiplaGenericsGlobalPharmaceuticalResearch

Cipla slashes price of generic cancer drug Nexavar in India by 76%; other cuts too

04-05-2012

Indian drugmaker Cipla (BSE: 500087) has slashed the prices of certain life-saving cancer drugs used…

Asia-PacificAstraZenecaBayerCiplaGenericsIressaMerck & CoNexavarOncologyPharmaceuticalPricingTemodar

Back to top